Summary
The pharmacokinetics of isradipine, a calcium-channel blocker, have been studied in eight patients on chronic haemodialysis. A single oral dose of 5 mg was administered on both a non-haemodialysis and a haemodialysis day and the plasma concentrations of isradipine were analyzed.
The mean cmax, tmax, AUC, and t1/2 in plasma on the non-haemodialysis day were 5.2 ng·ml−1, 1.4 h, 23.8 ng·h·ml−1, and 3.1 h, respectively. The dialysis clearance of isradipine was negligible (5.0 ml·min−1).
The t1/2 values during haemodialysis were not significantly different from those observed during the same period post dose on the non-haemodialysis day. The study demonstrates that supplemental doses of isradipine are not necessary in these patients since isradipine is not significantly removed by haemodialysis.
This is a preview of subscription content, log in via an institution to check access.
References
Pedersen OL, Krussel LR, Sihn I, Jespersen LT, Thomson K (1988) Long-Term Effects of Isradipine on Blood Pressure and Renal Function. Am J Med 86 [Suppl 4A]: 15–18
Handler CE, Rosenthal E, Tsagadopoulos D, Najn Y (1988) Comparison of Isradipine and Nifedipine in Chronic Stable Angina. Int J Cardiol 18: 15–26
Chandler HH, Schran HF, Cutler RE, Smith AJ, Gonsun LM, Blouin RA (1988) The Effects of Renal Function on the Disposition of Isradipine. J Clin Pharmacol 28: 1076–1080
Jean C, Laplanche R (1988) Assay of Isradipine and of its Major Metabolites in Biological Fluids by Capillary Gas Chromatography and Chemical Ionization Mass Spectrometry. J Chromatogr 428: 61–69
MicroMath Inc, Copyright 1988 RSTRIP, Polyexponential Curve Stripping/Parameter Estimation, Version 3.1
Ching-san CL, Marbury TC (1984) Drug Therapy in Patients Undergoing Haemodialysis. Clinical Pharmacokinetic Considerations. Clin Pharmacokinet 9: 42–66
Gipson TP (1985) Problems in Designing Hemodialysis Drug Studies. Pharmacotherapy 5: 23–29
Abernethy DR, Schwartz JB (1988) Pharmacokinetics of Calcium Antagonists Under Development. Clin Pharmacokinet 15: 1–14
Kleinbloesem CH, van Brummelen P, van de Linde JA, Voogd PJ, Breimer DD (1984) Nifedipine: Kinetics and Dynamics in Healthy Subjects. Clin Pharmacol Ther 35: 742–749
Foster TS, Hamann SR, Richards VR, Bryant PJ, Graves DA, McAllister RG (1983) Nifedipine Kinetics and Bioavailability After Single Intravenous and Oral Doses in Normal Subjects. J Clin Pharmacol 23: 161–170
Kleinbloesem CH, van Brummelen P, Faber H, Danhof M, Vermeulen NPE, Breimer DD (1984) Variability in Nifedipine Pharmacokinetics and Dynamics: A New Oxidation Polymorphism in Man. Biochem Pharmacol 33: 3721–3724
Boelaert J, Valcke Y, Dammekens H, DeVriese G, Ahr G, Schurgers M, Daneels R, Bogaert MG (1988) Pharmacokinetics of Nisoldipine in Renal Dysfunction. Eur J Clin Pharmacol 34: 207–209
Schran HF, Jaffe JM, Gonasun LM (1988) Clinical Pharmacokinetics of Isradipine. Am J Med 84 [Suppl 3B]: 80–89
Follath F, Taeschner W (1988) Clinical Pharmacology of Calcium Antagonists. J Cardiovasc Pharmacol 12 [Suppl 6]: S98-S100
Hanyok JJ, Chow MSS, Kluger J, Izard MW (1988) An Evaluation of Pharmacokinetics, Pharmacodynamics and Dialyzability of Verapamil in Chronic Hemodialysis Patients. J Clin Pharmacol 28: 831–836
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schönholzer, K., Marone, C. Pharmacokinetics and dialysability of isradipine in chronic haemodialysis patients. Eur J Clin Pharmacol 42, 231–233 (1992). https://doi.org/10.1007/BF00278492
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00278492